Color Genomics: Democratizing Access to Genetic Testing

Recognizing the revolution in genomic sequencing and its potential impact on diseases like breast cancer, we were thrilled to invest in Color Genomics last year.

Color Genomics offers a clinical-grade, comprehensive genetic test for breast and ovarian cancer risk at an affordable price ($249 vs. $4,000). With 10-15% of the breast and ovarian cancer cases linked to genetic mutations, we see the opportunity for better early detection and awareness. Despite this opportunity, genetic testing was economically unavailable to 90% of people due to high costs and insurance criteria. However, Color Genomics is opening a new market with its unique approach: its ability to use a small saliva sample and analyze 19 genes - including BRCA1 and BRCA2 - for 10x cheaper. We are excited about how Color Genomics is democratizing access to genetic testing, empowering women and men to take control of their health, and revolutionizing the prevention, detection, and treatment paradigm.

October is particularly significant as we kick off Breast Cancer Awareness month with the launch of the Color Genomics Benefits Program. Innovation Endeavors joins 18 leading Bay Area companies to make genetic testing for breast and ovarian cancer risk genes available to all of their employees as a corporate benefit. By participating in this program, we pledge to cover 100% of the cost of the Color Test for all employees during the month of October. We are empowering our employees to take a proactive approach to their health. 

We encourage our friends in the Valley and beyond to join us by taking part in the Color Genomics Benefits Program. For more information, please visit:

To continue the conversation, sign up for our newsletter here.